Pure Global AI
NCT06409429Not yet recruiting

Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Tianjin Medical University Cancer Institute and HospitalPhase 2/3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
Nimotuzumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tianjin Medical University Cancer Institute and Hospital
Location
Tianjin, China
Timeline & enrollment
Phase
Phase 2/3
Start date
May 01, 2024
End date
May 30, 2027
Enrollment
146 participants
Primary outcome

relapse-free survival (RFS)

Summary

This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The
 main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab
 combined with GX for postoperative adjuvant treatment of pancreatic cancer.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06409429
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06409429 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 146 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.